Price Alert: June 16, 2025 — The new Kintor Green Version with 0.5% KX-826 plus various natural ingredients is currently on sale for almost 70% off (after including the 15% off coupon option below the price). So it will cost just $28 after taxes. Very strange, as the other two products are not similarly discounted. If you were thinking of ever trying this product, it is hard to believe that you will ever get a better price. Hope it is not an error.
See my regularly updated post on China-based Kintor Pharmaceutical’s clinical trials for their two main topical androgen receptor targeting products. Both may come out in the next few years if Phase 3 trials are successful.
Meanwhile, the company launched a KX-826 (Pyrilutamide) based cosmetic product in 2024 after receiving International Nomenclature Cosmetic Ingredient (INCI) approval.
Update: June 2025
Kintor now sells three versions of its KX-826 spray for hair loss.
The new green version with 0.5% KX-826. It comes with a plant-based extract essence that promotes scalp blood circulation and nutrition to hair follicles. The full list of natural ingredients can be seen here.
The Kintor KX-826 spray for hair loss now comes in three versions.
July 26, 2024
KX-826 Hair Growth Spray Launched
The blue version is priced at $69 for a 1-month supply (plus a 5% off coupon) and contains 0.5% KX-826 (pyrilutamide). Update: The enhanced 0.9% KX-826 purple version is also on Amazon now. Both are made by Koshine Biomedica (China) in Hong Kong.
Each product comes as a topical spray. There are no reviews or product ratings at the time of writing this post. The product description mentions that it is a dihydrotestosterone (DHT) blocker, and reduces sebum excretion and scalp oiliness.
Note that the actual androgen receptor antagonist KX-826 is still in Phase 3 clinical trials in the US and China. The cosmetic product (image below) is a way for the company to release a topical product faster.
Kintor Pharmaceutical (China)’s KX-826 Cosmetic Androgen Receptor Antagonist. Made by Koshine Biomedica (China).
Also of interest, one of the images on Amazon implies more rapid hair growth from this spray product in comparison to FDA approved Minoxidil:
KX-826 versus Minoxidil hair growth comparison.
Usage Instructions
The instructions on using this KX-826 spray are as follows:
Open the outer packaging and insert the spray head onto the bottle.
Find your area of hair loss, use your fingers to expose the scalp, and then apply th30e anti-hair loss liquid spray.
Use once in the morning and once in the evening. For a total of 6-8 sprays each time, which equates to about 1ml.
Massage the scalp for about 3 minutes after the spray has been applied.
Note: Only meant to be used when your scalp and hair are both dry.
Clinical Observational Study finds KX-826 plus Minoxidil to be Superior
Kintor just published the primary endpoint results of its observational study on using KX-826 in combination with Minoxidil. Thanks to “Kevin Mann” for posting about this in our Discord chat. Key quote:
“After 24 weeks of treatment, the TAHC of the Combination Drugs Group showed an increase of 30.54 hairs/cm2 from baseline. This was 10.29 hairs/cm2 more than the Minoxidil Group,”
A total of 40 Chinese patients took KX-826 tincture 0.5% BID (i.e. twice per day) plus minoxidil tincture 5% BID in the combination group. The Minoxidil only group had 35 participants. All 75 enrollees suffered from androgenetic alopecia. Interestingly, at week 24, there were 11 patients with TAHC change from baseline ≥40 hairs/cm². Of these, 10 patients were in the Combination Drugs Group.
To me, these results are as expected when compared to the Phase 3 results of KX-826 by itself that I wrote about in the March 21, 2025 update.
Update: April 29, 2025
Kintor KX-826 to get Released in China in 2027
Kintor’s Annual Report for 2024 was released yesterday (h/t “Rex”). In regards to commercialization for KX-826, Kintor expects to submit a NDA to the Chinese NMPA in 2026. If the application is successful, commercialization of KX-826 in China is expected in 2027. They have updated their pipeline page, which includes trials for both KX-826 and GT20029 in China and the US.
Update: March 21, 2025
Phase III Clinical Trial Of KX-826 Reaches Primary Endpoint
Kintor Pharmaceutical just announced that the long-term safety Phase III clinical trial of its first-in-class KX-826 (pyrilutamide) tincture for the treatment of androgenetic alopecia has reached its primary endpoint. The results are very good, the safety profile is excellent and therefore the company’s stock price went up a stunning 51% so far today. The first person in this 52-week trial was enrolled on 19 July 2023. The results demonstrated excellent safety and efficacy. Key highlights:
46% of patients saw a ≥10 hairs/cm2 change in total area hair count (TAHC) from baseline.
20% of patients saw a ≥20 hairs/cm2 change in TAHC.
Note that this clinical trial involves a total of 16 clinical research centers in China. It seems like earlier “pre” primary endpoint positive results were also released last year (see my update from October 17, 2024).
Even better news is that this trial used KX-826 tincture 0.5% BID (twice per day) as the dosage. Kintor also began a Phase III trial for the higher-dose 1.0% at the beginning of 2025. That dose might give even better results.
Kintor has enrolled its first subject in the Phase III pivotal clinical trial of its KX-826 tincture 1.0% in China for the treatment of male androgenetic alopecia. Note that the Phase III results for the 0.5% dosage were released in 2024 (see further below) and total area hair counts increase by around 10%, with results lasting even at 52 weeks.
The 1.0% dosage will likely lead to even better results based on prior preclinical findings. Kintor plans to recruit 666 patients and complete the trials by the end of 2025.
Update November 29, 2024
Earlier this week, scientists from Kintor Pharmaceutical (and Koshine Medical) did a Reddit AMA. Some of the highlights:
They are currently developing a 2% foam version of KX-826, though the timeline for its release is yet to be determined.
Phase 3 trials for GT20029 are planned in China in 3Q 2025. US will be 6 months later. This is for the actual medication, and not for a cosmetic (for which such trials are not required).
GT20029 has the potential “to be revolutionary” for AGA treatment. They have found that once-a-week dosing with GT20029 demonstrated similar efficacy to daily dosing. this is a significant advantage compared to the twice-a-day dosing required for treatments such as Minoxidil, CB-03-01 (Breezula), and KX-826 (Pyrilutamide).
Update October 17, 2024
Kintor Releases Phase 3 Results for KX-826 at a 0.5% Dosage. Now they will Test 1.0%.
A new update on KX-826 (Pyrilutamide) Phase 3 Trials from Kintor that is not yet on their website.
They have completed the first subject enrollment in the pivotal Phase II/III clinical trial of KX-826 tincture 1.0% for the treatment of male adult androgenetic alopecia in China. The company’s preclinical studies have shown that the KX-826 tincture 1.0% has a significantly higher retention rate in human scalp cells compared to the KX-826 tincture 0.5%. and good chance at showing greater efficacy. The latter lower dose was used in the previous Phase III clinical trial (see next point).
They also give results of the Chinese Phase III clinical trials for the 0.5% dosage. This trial entailed the use of KX-826 tincture 0.5% BID (twice per day) on 95 male patients for 52 weeks. There were no serious adverse events reported. In terms of efficacy, after 12, 24, 36 and 52 weeks of treatment, both total area hair count (TAHC) and target area non-vellus hair width (TAHW) showed an increase from baseline. The TAHC increased by 9.5%, 13.0%, 11.4% and 9.7% respectively, while the TAHW increased by 12.1%, 18.6%, 15.7% and 10.0% respectively. So the best results are at 24 weeks, though there is still significant positive growth at 52 weeks.
Kintor Pharmaceutical: KX-826 and GT20029 for Androgenetic Alopecia
My original post on Kintor Pharmaceutical (China) has become way too lengthy after so many updates. Therefore I will add all new developments in this post (below this product introduction section).
This rapidly moving well funded company is in Phase 2 and Phase 3 trials in the US and China for both its male androgenetic alopecia (AGA) products. Kintor (pipeline here) is conducting hair loss trials for:
Two separate androgen receptor (AR) targeting products: a degrader (GT20029) and an antagonist (KX-826 aka Pyrilutamide).
Each of these trials is being conducted in both China and the US.
Each of these products is being tested for both males and females with androgenetic alopecia (aka pattern hair loss).
i.e., a total of 8 types of clinical trials times 3 phases in each = 24 developments we have to track. A bit too much if all of these do end up taking place, but a most welcome development. Over one-half of these 24 potential trials are already finished.
The GT20029 product is an androgen receptor degrader (AR Degrader). It is developed using Kintor’s proprietary Proteolysis Targeting Chimera (PROTAC) platform. This is the world’s first topical androgen receptor (AR) compound (AR-PROTAC) to enter clinical trials. GT20029 degrades the AR protein via the E3 ubiquitin ligase pathway. During preclinical studies, GT20029 did not cause any notable side effects or systemic drug accumulation.
Kintor’s main product for treating male pattern hair loss is KX-826 (Pyrilutamide) and is an androgen receptor antagonist (AR Antagonist). KX-826 is currently in Phase 3 clinical trials in both China and the US per the pipeline chart. In China, these trials are now completed.
Note that Cassiopea’s Breezula (Clascoterone) is an AR antagonist that is also currently in Phase 3 trials in the US. Kintor’s website has an interesting article discussing both these competing AR antagonist products and hair loss.
Kintor Launches Cosmetics with KX-826 as the Main Ingredient
Kintor Pharmaceutical has officially launched a line of cosmetics with KX-826 as the main ingredient. This is the second widely discussed hair loss product that has been launched in the past two years as a cosmeceutical (with the first being CosmeRNA).
Update: June 5, 2024
KX-826 Receives The INCI Cosmetic Designation
Kintor Pharmaceutical’s KX-826 (Pyrilutamide) has received the International Nomenclature Cosmetic Ingredient (INCI) approval from the International Cosmetic Ingredient Nomenclature Committee. The assigned INCI name is Methylpyridinyl Fluoromethoxybenzonitrile Dimethyloxothiooxoimidazolidine. INCI names are recognized worldwide when identifying cosmetic ingredients. This development will facilitate the potential future global launch of Kintor’s line of cosmetics that have KX-826 as the main ingredient.
Update: May 24, 2024
More Effective KX-826 Tincture 1.0% versus 0.5%
Kintor’s clinical trial of KX-826 tincture 1.0% for treating male androgenetic alopecia in China just received clearance. The company’s pre-clinical studies showed that KX-826 tincture 1.0% had a significantly higher retention concentration level on human scalp cells compared to KX-826 tincture 0.5%. The latter was used in the Kintor’s previous phase III clinical trial.
Update: April 22, 2024
Positive Update on GT20029 Phase 2 Clinical Trial
Kintor Pharmaceutical just announced that its China Phase II clinical trial of its first-in-class androgen receptor (AR) proteolysis targeting chimera (PROTAC) compound GT20029 for treating androgenetic alopecia has reached the primary endpoint. The results are statistically significant and clinically meaningful, while safety and tolerability is good.
GT20029 demonstrated statistically significant efficacy compared to placebo in both the QD (once a day) and BIW (twice a week) dosing cohorts.
After 12 weeks of treatment, the 0.5% QD GT20029 group showed an increase of 16.80 hairs/cm² from baseline. This was 6.69 hairs/cm² more than the placebo group.
The total area hair count (TAHC) of GT20029 1.0% BIW group showed an increase of 11.94 hairs/cm² from baseline. This was 7.36 hairs/cm² more than the placebo.
The 1% BIW dosage of GT20029 was identified as the optimal dosing level and has been recommended for the phase III clinical trial in China.
Key Quote:
“Based on the results of the Phase II clinical trial, the company will actively deploy subsequent clinical strategies for GT20029, such as initiating a phase III clinical trial in China and a phase II clinical trial in the US for male AGA.”
Update: February 1, 2024
Clinical Trial of KX-826 and Minoxidil
Kintor Pharma is undertaking clinical trials for two different androgen receptor targeting hair loss products (KX-826 and GT20029); in two countries (US and China); and for both males and females.
Now comes news that Kintor will also undertake Phase 1b/III clinical trials of KX-826 in combination with minoxidil for the treatment of androgenetic alopecia (AGA). The trial was just cleared by the National Medical Products Administration in China.
Update: November 27, 2023
Maybe Bad News for KX-826 Phase 3 Trial Results
According to this Reddit source, the results of the Chinese Phase 3 trials for KX-826 (aka Pyrilutamide) were ok, but not good enough. There were no serious adverse events or side effects. And positive hair growth was observed when compared to baseline (at all visit points) after 24 weeks. However, compared with the placebo group, the total area hair count (TAHC) improvement in the KX-826 treated group had no statistical significance. Albeit there was a “trend in efficacy observed”.
On a positive note, Kintor plans to continue with its multiple KX-826 related trials (in the US and China) for the topical treatment of androgenetic alopecia. I appreciate the speed with which the company released these findings. I expect there will be an official press release in the next few days. Edit: Seems like this never happened?
November 18, 2023
Phase 3 Trials for KX-826 (Pyrilutamide)
KX-826 (Pyrilutamide) is currently in the most advanced stage and has a good chance of coming to market in China by the end of 2024. In Kintor’s pipeline page, it is shown to be in the final stage of Phase 3 trials for men in China; and early stage of Phase 3 trials for men in the US. Moreover, it is also in the early stage of Phase 3 trials for women in China.
Kintor is also undertaking a second Phase 3 trial in China for long-term safety of KX-826, which I discussed in detail in my original post. Even more exciting, one my Chinese readers sent me the below partial translation of a new October 2023 presentation by Kintor. He said that his English is not good, but I only changed a few words that were confusing or out of place.
“KX-826 is a topical androgen receptor (AR) antagonist independently developed by Pioneer Pharmaceutical. It is the first AR antagonist in the world to enter phase III clinical trials for the treatment of hair loss. KX-826 binds the AR by competing with dihydrotestosterone (DHT) to locally block androgen-mediated signaling to limit hair follicle miniaturization and promote peripheral hair growth. After reaching the circulatory system, KX-826 is rapidly metabolized into inactivated metabolites, which has little influence on the whole body AR signaling pathway and has good safety.
The Phase II clinical trial in China included 120 men with hair loss. Of these, 90 subjects were randomly assigned to KX-826 0.25% twice daily, KX-826 0.5% once daily, and KX-826 0.5%, and the remaining 30 subjects were randomly assigned to placebo. After 24 weeks of treatment, the 0.5% concentration group of KX-826 showed a significant improvement in the amount of non-vellus hair in the target area. An increase of 22.73 roots per square centimeter compared to baseline.
Finally, news about Phase III: KX-826 is currently in or planned for five Phase III clinical trials (two in China and three in the United States). Among them, the Chinese Phase III clinical trial of KX-826 for male alopecia has completed the last subject visit, and the company is making full efforts to promote the data collation, library un-blinding and data statistical analysis of this clinical trial.”
Phase 2 Trials for GT2009
In Kintor’s August 22, 2023 update, they announced the completion of patient enrollment in Phase II clinical trials of GT20029 for male pattern hair loss in China. The current pipeline shows that these trials are almost over in China, and close to beginning in the US.
